I own both and continue to hold AVXL to comfort myself during NVIV recent regression, which I expect to reverse any day now. Not an either or for me. All the best.
88...agree, MJF grant is multiple blessings. Not only do they fund the trials but they give their name. Micro Bios like AVXL are golden when this kind of recognition is given. In some way it adds to the credibility of the entire effort and the development team. If we are real lucky the trials show no/low risk and promise of high efficacy. Many positives.
I am long as well, big P may be history if BioPharma is shown to work more effectively than ChemPharma. I think that may be what we are seeing. They relly have no options. If they keep dropping bilions in research that goes nowhere they are toast.
rocket, I have read the trial expansion comment several times and think that it is important. When patients/families (study participants) ask to have their trial extended it says a lot to me. We would normally be at the exclusive mercy of clinicians who study/review assess the trial data and usually and tell us what is happening, that is as good as it gets. Do not want read too much into this but have never seen patient comments before and I like it. Of course they are human and could be mistaken but my guess is they know when they feel better. A positive observation.
"Anavex had cash and cash equivalents of approximately $8.0 million as of June 30, 2015, compared with approximately $6.3 million as at March 31, 2015. Approximately $3.0 million was raised as a result of warrants exercised during the quarter. Cash was used in operations and for the advancement of clinical trial work. The Company has sufficient cash for approximately two years."
I did read the letter and thought it must be significant but did not completely get it. Break it down a little as to certainty. thx
235-agree with the notion and general direction suggesting that certainly something will change if trials produce similar results as current published trials. The mini-micro structure of AVXL could not even answer the phones, much less drive next steps. Between AD, Epilepsy, PD and Cancer it is hard tio imagine possible combinations and permutations pulling at limited resources. Huge $$$ and risks in competition. I see BP with license agreements, milestone fees, and royalties up the nose...AVXL becomes a platform for a whole new world of treatments.Buyouts, not so much at this point, although everybody has their price. I predict that some of that will play out quickly due to compelling patient drives (if same results). Anecdotes from patients stories are sure to swing us dayato day, which is great because those are much easier to deal with than cinical numbers. The FDA will certainly facilitate in a responsible manner but it will happen quickly. Staying in front of the SP-risk based multi variable curve will be tough but it's about time we had somehthng to feel good about.If the science performs as indicated, then SP will be driven by a combination of factors simultaneously. This is not Y=MX+B scenario. IMO.
If results in September show continued benefit to AD patients that is positive direct good news. Indirectly, the credibility of this technology team then takes a huge jump. When that happens the value of the rest of the pipeline goes up exponentially. It won't take much for the indirect effect on SP to be exponential, paricularly to BP. All the best.
With limited resources, partnering for licensed clinical/development would seem a great way to go. Develop product, gather information, gets $$$.
And, considering what we already have as a base, it's not if, but when. Patients need this and the world needs this, lets hope it goes well. All the best.
agree, just bought as much additional as I could get